Jing Sun
Shanghai Jiao Tong University School of Medicine, China
- Orcid: 000-0003-2110-5189
- Publications: N/A
- Citations: N/A
- Keywords: GI Cancer, Surgery, Matastasis, iron metabolism
Short Bio
- I am currently a member of the Department of GI Surgery/Shanghai Minimally Invasive Surgery Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. I've finished my residency training majored in general surgery in 2010 and now am working as one of the attending surgeons in the department. Meanwhile, I am also appointed as an associate professor in Surgical Oncology of Shanghai Jiao Tong University School of Medicine. Since March 2020, I’ve also conducted as the Chief in Department of General Surgery in Wuxi Branch of Ruijin Hospital, Wuxi, China. I work as an attending surgeon in Dept. of GI Surgery, Ruijin Hospital and Shanghai Minimally Invasive Surgery Center. My clinical duty is focused on the daily treatment for patients diagnosed with digestive diseases/hernia/thyroid diseases, especially malignancies. Current duties include: • Laparoscopic surgeries, including gastric surgeries, colorectal surgeries, surgical treatment for gallbladder disease, hernia repair, etc • Key Member of Multidisciplinary Team (MDT) for Gastric & Colorectal Cancer of Ruijin Hospital I conduct a wide range of research into the clinical trials and basic science researches/translational medicine of gastrointestinal cancer and surgical treatment. (A) Clinical Trials: I am currently in charge of the management and coordination of all the registered and non-registered clinical trials in Shanghai Minimally Invasive Surgery Center, the ongoing trials include but not limited as: 1. Mechanisms of Fate Evolution of Colorectal Adenocarcinoma Metastasis (NCT04714814). 2. Mechanism and Process Regulation for Colorectal Tumors (NCT04707482). (B) Basic Science Research: My research interest of basic science research is elucidating the mechanism of metastasis of human colorectal cancer, investigating the potential novel anti-metastatic target and drug development of human colorectal cancer. Current years, my research works are focusing on a novel tumor suppressor, named NDRG1. My research team has reported the potential ability of this interesting target against colorectal cancer progression. The future research direction of NDRG1 will probably be the mechanism of NDRG1 in modulating anti-EGFR drug resistance. Current projects include: • Elucidating the core molecular machinery of colorectal cancer progression • Elucidating the function and mechanism of tumor suppressor, N-myc downstream regulated gene 1 (NDRG1) in colorectal cancer • Investigating the role of cytoskeleton on colorectal cancer metastasis • The functional role of NDRG1 in anti-EGFR drug-resistance of colorectal cancer • The functional role of cytoskeletal molecular motor proteins in colorectal cancer (C) Translational medicine research: I mainly focus on two different aspects: 1. Artificial intelligence in gastrointestinal cancer treatment. As one of the pioneer doctors who first applied IBM Watson Oncology into Chinese cancer patient care, I am currently working together with the engineers and physicians from MSKCC on the localization of Watson Oncology System in China. 2. Novel technique and technology innovation in minimally invasive surgery. I am currently working with two scientific institutions in the development of the new surgical instruments for minimally invasive surgery, such as robotic camera holder and trans-anal surgery platform.
